Mitochondrial medicine company NeuroVive Pharmaceutical AB (STO:NVP) reported on Thursday loss before tax of SEK14,982,000, or SEK0.20 per diluted share, for the third quarter of 2018, from July 2018 to September 2018.
This was a decline over loss before tax of SEK13,179,000, or SEK0.26 per diluted share, in Q3 2017.
Net revenues from the quarter were nil, same as in Q3 2017.
During January 2018 to September 2018, NeuroVive received positive FDA feedback on its NeuroSTAT TBI development plan, NeuroVive and Yungjin reported positive KL1333 phase I clinical study result and KL1333 received FDA Orphan Drug Designation for treatment of mitochondrial diseases.
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Perrigo announces quarterly dividend increase
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva
Biosenic finalises agreement with Phebra for oral arsenic troxide development